Loading...
A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer
BACKGROUND: Cabozantinib can enhance the effect of abiraterone in preclinical prostate cancer models. This study aimed to define the recommended phase 2 dose (RP2D) and preliminary efficacy of abiraterone+cabozantinib in mCRPC. METHODS: Patients with progressive mCRPC with 0–2 prior chemotherapy reg...
Saved in:
| Published in: | Prostate |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6286224/ https://ncbi.nlm.nih.gov/pubmed/29882250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23662 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|